Monday, July 28, 2014 7:28:17 PM
Your post to me starts with this statement:
Where did you hear the word? All news to me. Did you just give the word?
If what you say is true. Shocking.
You ask:
I am sure Dr. Diwan will do whatever is in his best financial interests regarding funds received from sale of the lab. If I were him, I probably would not be buying additional shares of NNVC. He is already overweight in his NNVC investments, and should be looking for diversification. This is what any prudent person would likely do. But, who knows? Dr. Diwan could surprise. His inside purchases of NNVC shares, at the market plus, says quite a bit concerning his confidence in the company. Not sure it was fair, to him, the way his last purchase of NNVC was administered. As I recall, he had to pay higher than market prices for his shares to eliminate any differential profits from his sale of shares for the funding of the lab. SEC rules, I think.
You ask:
He would not have a choice. Being an executive of NNVC, any shares he owns would be restricted shares.
You ask:
There will always be a percent of unhappy campers in the market, no matter what NNVC does or does not do. There was a tremendous amount of criticism concerning the fact NNVC was going to lease the lab, and the terms of the lease, etc. This is what started NNVC's reexamination of the situation. I think it was the appearance of possible conflicts of interest that got the discussion rolling. That and a better financial situation for the company. I don't know how the market will ultimately react. Suppose lots will depend on the details. But, NNVC had little choice, because without purchasing the lab, there would likely be endless criticisms of the situation. At least by buying the labs, the company may take a hit but will, in time, put the whole episode behind them. Damned if they did and damned if they didn't.
You ask:
Please, research for yourself the details. The details are available in many company filings. I say this, because the situation is complicated, and I am no patent or contractual expert. But, from my understanding, NNVC's agreements give them exclusivity to a wide range of enumerated uses for the base technologies and patents. This exclusive arrangement has contractual limited disclaimers. Also, I am pretty sure the terms will be extended to additional uses for the technology, unforeseen, at the time of the original agreement.
As a follow on the last question, you ask:
I think the two discussions are non sequitur. The ultimate relevance of the lab purchase is not dependent on the terms of the license or patent agreements. But, would I like to know the future results of TOX now. Yes, but I can not know the future. Darned. If I knew the future outcome of TOX, I could be rich. If management knew the future of TOX, they could make better decisions for the future, too. But, I don't think they can Ouija Board and better than I can, or even you can.
So we are stuck with a process. FDA requirements. No instant gratification. No fortunetelling of the future before the future arises. Just best guesses, reasonable deductions, risk and reward.
Bunny, most times I think you are funny; but, I take what you say seriously. Always, enjoy reading your posts.
Best of luck.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM